Real-World Risk of Gastrointestinal Bleeding for Direct Oral Anticoagulants and Warfarin Users: A Distributed Network Analysis Using a Common Data Model
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Early studies on direct oral anticoagulants (DOACs) reported a higher risk of gastrointestinal bleeding (GIB) compared with warfarin; however, recent studies have reported a reduced risk. Therefore, this study was designed to evaluate the risk of GIB in users of DOAC and warfarin. Methods: Using a common data model, we investigated the comparative risk of GIB in subjects from eight hospitals who were newly prescribed DOACs or warfarin. We excluded subjects who had a prior history of GIB or had been prescribed both medications. After propensity score matching, we analyzed 3,347 matched pairs of new DOAC and new warfarin users. Results: The risk of GIB in new DOAC users was comparable to that in new warfarin users (hazard ratio [HR], 0.95; 95% confidence interval [CI], 0.65 to 1.40; p=0.808). New DOAC users had a similar risk of GIB to new warfarin users among older patients >65 years (HR, 1.00; 95% CI, 0.69 to 1.52; p=0.997) and in older patients >75 years (HR, 1.21; 95% CI, 0.68 to 2.10; p=0.509). In addition, the risk of GIB was not significantly different between two groups according to sex. We also found that the risk of GIB in DOAC users was 26% lower in edoxaban or apixaban subgroups compared to rivaroxaban or dabigatran subgroups (HR, 0.74; 95% CI, 0.69 to 1.00; p=0.049). Conclusions: In real-world practice, the risk of GIB in new DOAC users is comparable to that in new warfarin users. In DOAC users, the risk of GIB was lower in edoxaban or apixaban subgroups than rivaroxaban or dabigatran subgroups.
Abstract
Background/Aims: Early studies on direct oral anticoagulants (DOACs) reported a higher risk of gastrointestinal bleeding (GIB) compared with warfarin; however, recent studies have reported a reduced risk. Therefore, this study was designed to evaluate the risk of GIB in users of DOAC and warfarin. Methods: Using a common data model, we investigated the comparative risk of GIB in subjects from eight hospitals who were newly prescribed DOACs or warfarin. We excluded subjects who had a prior history of GIB or had been prescribed both medications. After propensity score matching, we analyzed 3,347 matched pairs of new DOAC and new warfarin users. Results: The risk of GIB in new DOAC users was comparable to that in new warfarin users (hazard ratio [HR], 0.95; 95% confidence interval [CI], 0.65 to 1.40; p=0.808). New DOAC users had a similar risk of GIB to new warfarin users among older patients >65 years (HR, 1.00; 95% CI, 0.69 to 1.52; p=0.997) and in older patients >75 years (HR, 1.21; 95% CI, 0.68 to 2.10; p=0.509). In addition, the risk of GIB was not significantly different between two groups according to sex. We also found that the risk of GIB in DOAC users was 26% lower in edoxaban or apixaban subgroups compared to rivaroxaban or dabigatran subgroups (HR, 0.74; 95% CI, 0.69 to 1.00; p=0.049). Conclusions: In real-world practice, the risk of GIB in new DOAC users is comparable to that in new warfarin users. In DOAC users, the risk of GIB was lower in edoxaban or apixaban subgroups than rivaroxaban or dabigatran subgroups.
참고문헌 (28)
- Kirchhof P, "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)
- Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
- Abraham NS, "Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin : population based cohort study", BMJ, 350, pp.h1857~ (2015)
- Radaelli F, "What gastroenterologists should know about direct oral anticoagulants", Dig Liver Dis, 52, pp.1115~1125 (2020)
- Camm AJ, "Understanding the value of real-world evidence : focus on stroke prevention in atrial fibrillation with rivaroxaban", Thromb Haemost, 118, pp.S45~S60 (2018)
- Gu ZC, "Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 18, pp.792~799 (2020)
- Benamouzig R, "Review article : gastrointestinal bleeding risk with direct oral anticoagulants", Cardiovasc Drugs Ther, 36, pp.973~989 (2022)
- Lee HJ, "Risk of upper gastrointestinal bleeding in patients on oral anticoagulant and proton pump inhibitor co-therapy", PLoS One, 16, pp.e0253310~ (2021)
- Dong Y, "Prevention of non-vitamin K oral anticoagulants-related gastrointestinal bleeding with acid suppressants : a systematic review and meta-analysis", Clin Appl Thromb Hemost, 28, pp.10760296211064897~ (2022)
- Hripcsak G, "Observational Health Data Sciences and Informatics(OHDSI) : opportunities for observational researchers", Stud Health Technol Inform, 216, pp.574~578 (2015)
- Overhage JM, "Validation of a common data model for active safety surveillance research", J Am Med Inform Assoc, 19, pp.54~60 (2012)
- Yoon D, "Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research", Healthc Inform Res, 22, pp.54~58 (2016)
- Seo SI, "Association between proton pump inhibitor use and gastric cancer : a population-based cohort study using two different types of nationwide databases in Korea", Gut, 70, pp.2066~2075 (2021)
- You SC, "Conversion of National Health Insurance Service-National Sample Cohort(NHIS-NSC)Database into Observational Medical Outcomes Partnership-Common Data Model(OMOP-CDM)", Stud Health Technol Inform, 245, pp.467~470 (2017)
- Rijnbeek PR, "Converting to a common data model: what is lost in translation? Commentary on "fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model"", Drug Saf, 37, pp.893~896 (2014)
- Cheung KS, "Gastrointestinal bleeding in patients on novel oral anticoagulants : risk, prevention and management", World J Gastroenterol, 23, pp.1954~1963 (2017)
- Deitelzweig S, "Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients", Therap Adv Gastroenterol, 14, pp.1756284821997352~ (2021)
- Holster IL, "New oral anticoagulants increase risk for gastrointestinal bleeding : a systematic review and meta-analysis", Gastroenterology, 145, pp.105~112 (2013)
- Avgil-Tsadok M, "Dabigatran use in elderly patients with atrial fibrillation", Thromb Haemost, 115, pp.152~160 (2016)
- Graham DJ, "Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation", Circulation, 131, pp.157~164 (2015)
- Romanelli RJ, "Dabigatran versus warfarin for atrial fibrillation in realworld clinical practice : a systematic review and meta-analysis", Circ Cardiovasc Qual Outcomes, 9, pp.126~134 (2016)
- Lin L, "Clinical and safety outcomes of oral antithrombotics for stroke prevention in atrial fibrillation : a systematic review and network meta-analysis", J Am Med Dir Assoc, 16, pp.1103~ (2015)
- Kato ET, "Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation", Ageing Res Rev, 49, pp.115~124 (2019)
- Ballestri S, "Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism : a narrative review", Adv Ther, 40, pp.41~66 (2023)
- Malik AH, "Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients >75 years of age", Am J Cardiol, 123, pp.2051~2057 (2019)
- Ray WA, "Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation", JAMA, 326, pp.2395~2404 (2021)
- Kim Y, "Risks of long-term use of proton pump inhibitor on ischemic vascular events : a distributed network analysis of 5 real-world observational Korean databases using a common data model", Int J Stroke, 18, pp.590~598 (2023)
- Schuster T, "Propensity score model overfitting led to inflated variance of estimated odds ratios", J Clin Epidemiol, 80, pp.97~106 (2016)